New Delhi, Aug. 27 -- India's Contract Research, Development, and Manufacturing Organisation (CRDMO) sector, currently valued at around USD 3 billion, is set to grow rapidly in the coming years.
According to a report by Jefferies, the industry is expected to expand at an 18% compound annual growth rate (CAGR) from FY25 to FY30, outpacing the 14% growth seen over the past five years.
This growth is being driven by several key factors. Global pharmaceutical companies are increasingly adopting the "China+1" strategy, diversifying their supply chains to reduce dependence on China.
Additionally, rising demand for treatments targeting obesity and type 2 diabetes, along with advancements in antibody-drug conjugates (ADCs), is further boosting...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.